These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 3591456

  • 1. Improved survival in multiple myeloma with renal failure.
    Wahlin A, Löfvenberg E, Holm J.
    Acta Med Scand; 1987; 221(2):205-9. PubMed ID: 3591456
    [Abstract] [Full Text] [Related]

  • 2. Improved survival in multiple myeloma with combination chemotherapy and plasmapheresis.
    Wahlin A, Holm J, Nyström L.
    Haematologia (Budap); 1984; 17(4):465-71. PubMed ID: 6532916
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A.
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [Abstract] [Full Text] [Related]

  • 6. Management of renal complications in patients with advanced multiple myeloma.
    Viertel A, Weidmann E, Ditting T, Geiger H.
    Leuk Lymphoma; 2000 Aug; 38(5-6):513-9. PubMed ID: 10953972
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis.
    Yu X, Gan L, Wang Z, Dong B, Chen X.
    Int J Clin Pharmacol Ther; 2015 May; 53(5):391-7. PubMed ID: 25816886
    [Abstract] [Full Text] [Related]

  • 8. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U, Crivellari D, Carbone A, Veronesi A, Galligioni E, Trovò MG, Tumolo S, Grigoletto E.
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [Abstract] [Full Text] [Related]

  • 9. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
    Gola A, Usnarska-Zubkiewicz L, Wołowiec D, Urbaniak-Kujda D, Kotlarek-Haus S.
    Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
    [Abstract] [Full Text] [Related]

  • 10. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
    Carlson K, Hjorth M, Knudsen LM, Nordic Myeloma Study Group.
    Br J Haematol; 2005 Mar; 128(5):631-5. PubMed ID: 15725084
    [Abstract] [Full Text] [Related]

  • 11. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [Abstract] [Full Text] [Related]

  • 12. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
    Bladé J, San Miguel JF, Fontanillas M, Alcalá A, Maldonado J, García-Conde J, Conde E, Conzález-Brito G, Moro MJ, Escudero ML, Trujillo J, Pascual A, Rozman C, Estapé J, Montserrat E.
    J Clin Oncol; 1996 Jul; 14(7):2167-73. PubMed ID: 8683251
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C, Ardiet C, Bret M, Laville M, Fiere D, Tranchand B, Fouque D.
    J Nephrol; 2002 Jul; 15(6):684-9. PubMed ID: 12495285
    [Abstract] [Full Text] [Related]

  • 15. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Le Loët X, Monconduit M, Menard JF, Deshayes P, Grobois B, Tanguy A, Prevost E, Piguet H.
    Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
    [Abstract] [Full Text] [Related]

  • 16. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Bladé J, San Miguel JF, Alcalá A, Maldonado J, Sanz MA, García-Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A.
    J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
    [Abstract] [Full Text] [Related]

  • 17. Management of myeloma kidney: an anti-light-chain approach.
    Misiani R, Tiraboschi G, Mingardi G, Mecca G.
    Am J Kidney Dis; 1987 Jul; 10(1):28-33. PubMed ID: 3111253
    [Abstract] [Full Text] [Related]

  • 18. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM, Leong T, Lenhard RE, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA.
    Cancer; 1999 Sep 15; 86(6):957-68. PubMed ID: 10491521
    [Abstract] [Full Text] [Related]

  • 19. Treatment of multiple myeloma.
    San Miguel JF, Bladé Creixenti J, García-Sanz R.
    Haematologica; 1999 Jan 15; 84(1):36-58. PubMed ID: 10091392
    [Abstract] [Full Text] [Related]

  • 20. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
    Raab MS, Breitkreutz I, Hundemer M, Benner A, Klaus J, Hegenbart U, Moehler T, Ho AD, Zeier M, Goldschmidt H.
    Haematologica; 2006 Nov 15; 91(11):1555-8. PubMed ID: 17082013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.